| Ytd | 9.73% | |
| 1y | 747.32% |
| Open | Prev Close | 5.30 | Low | High | Mkt Cap | 555.92M | |||
| Vol | 0.00 | Avg Vol | 1.64M | EPS | -1.09 | P/E | -4.86 | Forward P/E | -0.19 |
| Beta | 0.41 | Short Ratio | 4.52 | Inst. Own | 46.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.58 | 200-d Avg | 5.09 | 1yr Est | 0.87 |
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in s
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-s
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock
US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follo
US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
On Friday, 209 companies set new 52-week lows.